- Home
- GF vs FATE Comparison
GF vs FATE Comparison
Compare GF & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GF
- FATE
- Stock Information
- Founded
- GF 1990
- FATE 2007
- Country
- GF Germany
- FATE United States
- Employees
- GF N/A
- FATE N/A
- Industry
- GF Investment Managers
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GF Finance
- FATE Health Care
- Exchange
- GF Nasdaq
- FATE Nasdaq
- Market Cap
- GF 155.4M
- FATE 152.4M
- IPO Year
- GF N/A
- FATE 2013
- Fundamental
- Price
- GF $10.98
- FATE $1.03
- Analyst Decision
- GF
- FATE Hold
- Analyst Count
- GF 0
- FATE 8
- Target Price
- GF N/A
- FATE $5.43
- AVG Volume (30 Days)
- GF 28.1K
- FATE 2.1M
- Earning Date
- GF 01-01-0001
- FATE 05-12-2025
- Dividend Yield
- GF 0.82%
- FATE N/A
- EPS Growth
- GF N/A
- FATE N/A
- EPS
- GF N/A
- FATE N/A
- Revenue
- GF N/A
- FATE $13,631,000.00
- Revenue This Year
- GF N/A
- FATE N/A
- Revenue Next Year
- GF N/A
- FATE N/A
- P/E Ratio
- GF N/A
- FATE N/A
- Revenue Growth
- GF N/A
- FATE N/A
- 52 Week Low
- GF $7.38
- FATE $0.66
- 52 Week High
- GF $9.41
- FATE $5.92
- Technical
- Relative Strength Index (RSI)
- GF 73.22
- FATE 46.14
- Support Level
- GF $10.30
- FATE $0.91
- Resistance Level
- GF $10.92
- FATE $1.34
- Average True Range (ATR)
- GF 0.14
- FATE 0.15
- MACD
- GF 0.07
- FATE -0.03
- Stochastic Oscillator
- GF 98.57
- FATE 20.69
About GF New Germany Fund Inc. (The)
NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.